Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to $80.1 million.

  • Macrogenics' Cash & Equivalents fell 5539.1% to $80.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.1 million, marking a year-over-year decrease of 5539.1%. This contributed to the annual value of $182.8 million for FY2024, which is 8110.86% up from last year.
  • Macrogenics' Cash & Equivalents amounted to $80.1 million in Q3 2025, which was down 5539.1% from $130.7 million recorded in Q2 2025.
  • In the past 5 years, Macrogenics' Cash & Equivalents registered a high of $224.3 million during Q1 2023, and its lowest value of $21.5 million during Q2 2022.
  • Its 5-year average for Cash & Equivalents is $125.8 million, with a median of $108.9 million in 2022.
  • In the last 5 years, Macrogenics' Cash & Equivalents crashed by 8863.89% in 2022 and then skyrocketed by 40658.16% in 2023.
  • Quarter analysis of 5 years shows Macrogenics' Cash & Equivalents stood at $123.5 million in 2021, then dropped by 11.81% to $108.9 million in 2022, then dropped by 7.28% to $101.0 million in 2023, then soared by 81.11% to $182.8 million in 2024, then plummeted by 56.18% to $80.1 million in 2025.
  • Its last three reported values are $80.1 million in Q3 2025, $130.7 million for Q2 2025, and $145.6 million during Q1 2025.